BERTIS

Pan-omics Analysis Service & Solution

PASS

PASS is a proteomics analysis and interpretation service that supports R&D
at pharmaceutical and biotech companies, research institutions, and hospitals.

PASS identifies and quantifies mass spectrometry-based proteomics data using our proprietary DEEP Platform,
and interprets the results biologically to help customers uncover disease-associated protein changes,
drug mechanisms of action, treatment responses, and novel target candidates.

Bertis possesses the core expertise and proprietary technology for pan-omics (multi-omics) analysis,
providing customized solutions wherever omics data analysis is applicable.
PASS not only enables frontier biological systems research through top-tier expertise, infrastructure, and equipment,
but also supports candidate selection, mechanism-of-action elucidation, off-target effect assessment, and prioritization of follow-up validation
by adding protein-level evidence to the genomic, transcriptomic, and efficacy data our customers already hold.

Essential
Service

Categorized by research objective and deliverable

Discovery
Discovery of novel targets and biomarker candidates
Quantification
Quantification of target protein abundance and condition-specific changes
Profiling
Analysis of protein composition and global changes in samples
Network
Interpretation of related pathways and mechanisms of action
PASSPowered by DEEP Platform

Drug Development
Applications

Examples of application areas in drug development

Target Discovery
Exploration of therapeutic targets and biomarker candidates
Mechanism of Action
Elucidation of candidate compound mechanisms of action
TPD
Assessment of target degradation and off-target effects
Exosome · HCP · ADC
Characterization and quality analysis of therapeutics

Analytical Capabilities — Integrated · Targeted · Single Cell Proteomics · Lipidomics · PTM · Bioinformatics (selected and combined according to research objectives)

With PASS, you can leverage Bertis’ scientific resources and cutting-edge tools to advance your research projects and goals, from the design stage to the interpretation and visualization of bioinformatics analysis results.

Analytical Capabilities

Organized by analytical approach (Integrated, Targeted), analytical unit (Single Cell), and analytical target (Lipidomics),
and selected and combined according to research objectives.

  • Integrated Proteomics
  • Targeted Proteomics
  • Single Cell Proteomics
  • Lipidomics

Integrated Proteomics

We identify various proteins within different samples using mass spectrometry-based methods and analyze quantitative changes to provide protein information associated with specific diseases or conditions.
PASS performs deep-coverage analysis using its automated fractionation technology (COFFER), and processes and interprets data with our proprietary DEEP platform (DEEP-find for protein identification and quantification, DEEP-mining for QC, statistical, and pathway analysis).

Application

biomarker discovery, drug target discovery, PTM analysis, modality-specific analysis (TPD, exosome),
characterization and process analysis of protein therapeutics (ADC, HCP)

Post-Translational Modification (PTM) Analysis

Provide analysis of PTMs (Post-Translational Modifications) in proteins that are difficult to interpretaste through RNA information.
Quantitative analysis of modified proteins and amino acids for the major in vivo PTMs (Phosphorylation, Acetylation, Methylation, Ubiquitination, Glycosylation).

Pharmaceutical CMC Quality Control

Modality-Specific Analysis (TPD, Exosome)

TPD: Evaluates whether target proteins are degraded, along with off-target and downstream pathway changes.
Exosome: Supports the assessment of quality attributes, including protein and lipid characteristics and batch-to-batch consistency.

Analysis of extracellular vesicle (exosome) therapeutics

Provide information for quality management to ensure equivalence and compliance to the ‘Development of Production Process and Quality Control Guidelines for Exosome-Based Therapeutics’ provided by the Ministry of Food and Drug Safety.

Analysis package: Comparative profiling of proteins, lipids, and RNA

TPD (Targeted Protein Degradation) Analysis

Provide the quantitative results of target protein degradation and regulation of downstream pathway proteins in response to drug treatment.
Bioinformatics analysis to elucidate the impact of off-target proteins. This approach allows us to under stand the effects exerted on off-target proteins in a comprehensive manner.

Analysis package: Proteomics and bioinformatics analysis

Targeted Proteomics

PASS provides accurate quantitative results based on targeted mass spectrometry approach such as MRM (Multiple Reaction Monitoring) and PRM (Product Reaction Monitoring) analysis.
This method utilizes internal standards (IS) in the form of isotopically labeled surrogate peptides for each target.
We have developed and provide a reproducible results that meets the validation guidelines outlined by the Ministry of Food and Drug Safety. This method ensures high reproducibility with a coefficient of variation (CV) of less than 15%.

Application

quality control of protein therapeutics (HCP), absolute quantification of proteins within samples, biomarker validation

Biopharmaceutical Quality Control (HCP)

We are capable of verifying the purity during the separation and purification of monoclonal antibody drugs and cell-based therapeutics.

Analysis package: Mass spectrometry-based analysis method
(Semi, Absolute quantification) as an alternative to ELISA analysis

Single Cell Proteomics

Single-cell technologies can serve as a starting point for the development of
effective personalized therapies and cures for diseases. In particular,
mass spectrometry-based single-cell proteomics provides unbiased results.
Bertis has introduced Bruker’s timsTOF SCP system, which provides meaningful
results even in true single-cell level.

Application

drug target discovery, spatial biology

Lipidomics

Lipids, consisting of over 4,000 diverse compounds, are present in various tissues and cellular compartments of the human body. They are being applied not only in cancer research but also in metabolic disease studies. The PASS service provides identification and quantification of lipids in samples using representative standard substances. Additionally, we provide profiling results of exosomal lipid composition according to the guidelines of the Ministry of Food and Drug Safety.

Application

quality analysis of new drugs (exosomes), Biomarker discovery

  • How much sample is required?

  • How should I send my samples?

  • How is QC for protein amount performed?

  • Do I need to perform sample preparation myself?

  • How is LC-MS/MS analysis performed?

  • What types of results are provided?

  • How long does the analysis take?

Service Request
Please use this form to submit your inquiry for Bertis PASS. We will be happy to review your request and respond in a timely manner.
Privacy Policy
By registering your details on our website, you consent to us collecting personal information for the purpose of responding to your inquiries. We understand the importance of protecting your privacy and will not use your personal information for anything other than to answer your inquiries.

I consent to the collection and use of my personal information collected by Bertis through legitimate channels for the purposes outlined in this policy.

  • Personal information collected: Your Name, Email, Contact, Company Name, Occupation
  • Purpose of data collection and use: Confirm the delivery of customer inquiries, contact the inquirer for fact checking, provide answers, notify inquiry results
  • Period of retention and use of personal information: To be retained for one year after the purpose of collection and use of personal information is met

* You have the right to refuse to consent to the collection and use of your personal information, and if you do not agree to these terms, your access to the service may be restricted.
* Your personal information will be destroyed without delay one year after the purpose of collecting and using personal information is met. However, if there is a duty to preserve personal information in accordance with Korean law or ordinance, it will be preserved for a certain period specified by the law.
  • Basis for data retention: Records on contract or subscription withdrawal, etc.
  • Retention period: 5 years

** Records of contracts, withdrawal of subscription, etc.: 5 years (Act on the Consumer Protection in Electronic Commerce, etc.)
** Records of payment and supply of goods, etc.: 5 years (Act on the Consumer Protection in Electronic Commerce, etc.)
** Records of handling customers’ complaints or disputes: 3 years (Act on the Consumer Protection in Electronic Commerce, etc.)

go top